aluates Reports

$ 0.0

Automative

Global Insulin Biologics and Biosimilars Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-18V13825

Global Insulin Biologics and Biosimilars Market Research Report 2023

BUY CHAPTERS

Global Insulin Biologics and Biosimilars Market Research Report 2025

Code: QYRE-Auto-18V13825

Report

May 2025

Pages:79

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

Sanofi

Gan & Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon Ltd.

WOCKHARDT

Insulin Biologics and Biosimilars Market Size

The global market for Insulin Biologics and Biosimilars was valued at US$ 28340 million in the year 2024 and is projected to reach a revised size of US$ 39940 million by 2031, growing at a CAGR of 5.1% during the forecast period.

Insulin Biologics and Biosimilars Market

Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.

The insulin biologics and biosimilars market is driven by the increasing prevalence of diabetes and the rising demand for effective and affordable insulin therapies. Insulin biologics play a critical role in managing diabetes and are widely used by patients worldwide. The growing diabetic population, along with the need for personalized and long-term insulin treatments, contributes to market growth. Additionally, advancements in biotechnology and insulin delivery systems have improved patient convenience and adherence. Biosimilars, which are highly similar versions of approved insulin biologics, offer cost-effective alternatives and have gained traction due to their potential to reduce healthcare expenditures and increase patient access. However, the market also faces challenges, including the complex regulatory pathway for biosimilars" approval, the need for extensive clinical comparability studies, and concerns regarding interchangeability and immunogenicity. Additionally, patent protection and market exclusivity of originator insulin products pose obstacles for biosimilar manufacturers. To succeed in this market, companies must navigate the regulatory landscape effectively, invest in research and development, demonstrate safety and efficacy of biosimilars, and collaborate with healthcare providers to promote the adoption of biosimilars and improve patient access to insulin therapies.

This report aims to provide a comprehensive presentation of the global market for Insulin Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Biologics and Biosimilars.

The Insulin Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Insulin Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Insulin Biologics and Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Insulin Biologics and Biosimilars Market Report

Report Metric	Details
Report Name	Insulin Biologics and Biosimilars Market
Accounted market size in year	US$ 28340 million
Forecasted market size in 2031	US$ 39940 million
CAGR	5.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Insulin Biologics Insulin Biosimilars
Segment by Application	Hospital Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Insulin Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Insulin Biologics and Biosimilars Market growing?

Ans: The Insulin Biologics and Biosimilars Market witnessing a CAGR of 5.1% during the forecast period 2025-2031.

What is the Insulin Biologics and Biosimilars Market size in 2031?

Ans: The Insulin Biologics and Biosimilars Market size in 2031 will be US$ 39940 million.

Who are the main players in the Insulin Biologics and Biosimilars Market report?

Ans: The main players in the Insulin Biologics and Biosimilars Market are Novo Nordisk, Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt

What are the Application segmentation covered in the Insulin Biologics and Biosimilars Market report?

Ans: The Applications covered in the Insulin Biologics and Biosimilars Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Insulin Biologics and Biosimilars Market report?

Ans: The Types covered in the Insulin Biologics and Biosimilars Market report are Insulin Biologics, Insulin Biosimilars

Recommended Reports

Diabetes Treatments

Biosimilars Market

Biologics & Proteins

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Insulin Biologics

1.2.3 Insulin Biosimilars

1.3 Market by Application

1.3.1 Global Insulin Biologics and Biosimilars Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Insulin Biologics and Biosimilars Market Perspective (2020-2031)

2.2 Global Insulin Biologics and Biosimilars Growth Trends by Region

2.2.1 Global Insulin Biologics and Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Insulin Biologics and Biosimilars Historic Market Size by Region (2020-2025)

2.2.3 Insulin Biologics and Biosimilars Forecasted Market Size by Region (2026-2031)

2.3 Insulin Biologics and Biosimilars Market Dynamics

2.3.1 Insulin Biologics and Biosimilars Industry Trends

2.3.2 Insulin Biologics and Biosimilars Market Drivers

2.3.3 Insulin Biologics and Biosimilars Market Challenges

2.3.4 Insulin Biologics and Biosimilars Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Insulin Biologics and Biosimilars Players by Revenue

3.1.1 Global Top Insulin Biologics and Biosimilars Players by Revenue (2020-2025)

3.1.2 Global Insulin Biologics and Biosimilars Revenue Market Share by Players (2020-2025)

3.2 Global Insulin Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Insulin Biologics and Biosimilars Revenue

3.4 Global Insulin Biologics and Biosimilars Market Concentration Ratio

3.4.1 Global Insulin Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Insulin Biologics and Biosimilars Revenue in 2024

3.5 Global Key Players of Insulin Biologics and Biosimilars Head office and Area Served

3.6 Global Key Players of Insulin Biologics and Biosimilars, Product and Application

3.7 Global Key Players of Insulin Biologics and Biosimilars, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Insulin Biologics and Biosimilars Breakdown Data by Type

4.1 Global Insulin Biologics and Biosimilars Historic Market Size by Type (2020-2025)

4.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Type (2026-2031)

5 Insulin Biologics and Biosimilars Breakdown Data by Application

5.1 Global Insulin Biologics and Biosimilars Historic Market Size by Application (2020-2025)

5.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Insulin Biologics and Biosimilars Market Size (2020-2031)

6.2 North America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Insulin Biologics and Biosimilars Market Size by Country (2020-2025)

6.4 North America Insulin Biologics and Biosimilars Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Insulin Biologics and Biosimilars Market Size (2020-2031)

7.2 Europe Insulin Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Insulin Biologics and Biosimilars Market Size by Country (2020-2025)

7.4 Europe Insulin Biologics and Biosimilars Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Insulin Biologics and Biosimilars Market Size (2020-2031)

8.2 Asia-Pacific Insulin Biologics and Biosimilars Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2020-2025)

8.4 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Insulin Biologics and Biosimilars Market Size (2020-2031)

9.2 Latin America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Insulin Biologics and Biosimilars Market Size by Country (2020-2025)

9.4 Latin America Insulin Biologics and Biosimilars Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Insulin Biologics and Biosimilars Market Size (2020-2031)

10.2 Middle East & Africa Insulin Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2020-2025)

10.4 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novo Nordisk

11.1.1 Novo Nordisk Company Details

11.1.2 Novo Nordisk Business Overview

11.1.3 Novo Nordisk Insulin Biologics and Biosimilars Introduction

11.1.4 Novo Nordisk Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.1.5 Novo Nordisk Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Details

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly Insulin Biologics and Biosimilars Introduction

11.2.4 Eli Lilly Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.2.5 Eli Lilly Recent Development

11.3 Sanofi

11.3.1 Sanofi Company Details

11.3.2 Sanofi Business Overview

11.3.3 Sanofi Insulin Biologics and Biosimilars Introduction

11.3.4 Sanofi Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.3.5 Sanofi Recent Development

11.4 Gan&Lee

11.4.1 Gan&Lee Company Details

11.4.2 Gan&Lee Business Overview

11.4.3 Gan&Lee Insulin Biologics and Biosimilars Introduction

11.4.4 Gan&Lee Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.4.5 Gan&Lee Recent Development

11.5 Tonghua Dongbao

11.5.1 Tonghua Dongbao Company Details

11.5.2 Tonghua Dongbao Business Overview

11.5.3 Tonghua Dongbao Insulin Biologics and Biosimilars Introduction

11.5.4 Tonghua Dongbao Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.5.5 Tonghua Dongbao Recent Development

11.6 United Laboratory

11.6.1 United Laboratory Company Details

11.6.2 United Laboratory Business Overview

11.6.3 United Laboratory Insulin Biologics and Biosimilars Introduction

11.6.4 United Laboratory Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.6.5 United Laboratory Recent Development

11.7 Geropharm

11.7.1 Geropharm Company Details

11.7.2 Geropharm Business Overview

11.7.3 Geropharm Insulin Biologics and Biosimilars Introduction

11.7.4 Geropharm Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.7.5 Geropharm Recent Development

11.8 Biocon

11.8.1 Biocon Company Details

11.8.2 Biocon Business Overview

11.8.3 Biocon Insulin Biologics and Biosimilars Introduction

11.8.4 Biocon Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.8.5 Biocon Recent Development

11.9 Wockhardt

11.9.1 Wockhardt Company Details

11.9.2 Wockhardt Business Overview

11.9.3 Wockhardt Insulin Biologics and Biosimilars Introduction

11.9.4 Wockhardt Revenue in Insulin Biologics and Biosimilars Business (2020-2025)

11.9.5 Wockhardt Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novo Nordisk

Eli Lilly

Sanofi

Gan & Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon Ltd.

WOCKHARDT

List of Tables

Table 1. Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Insulin Biologics

Table 3. Key Players of Insulin Biosimilars

Table 4. Global Insulin Biologics and Biosimilars Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Insulin Biologics and Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Insulin Biologics and Biosimilars Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Insulin Biologics and Biosimilars Market Share by Region (2020-2025)

Table 8. Global Insulin Biologics and Biosimilars Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Insulin Biologics and Biosimilars Market Share by Region (2026-2031)

Table 10. Insulin Biologics and Biosimilars Market Trends

Table 11. Insulin Biologics and Biosimilars Market Drivers

Table 12. Insulin Biologics and Biosimilars Market Challenges

Table 13. Insulin Biologics and Biosimilars Market Restraints

Table 14. Global Insulin Biologics and Biosimilars Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Insulin Biologics and Biosimilars Market Share by Players (2020-2025)

Table 16. Global Top Insulin Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin Biologics and Biosimilars as of 2024)

Table 17. Ranking of Global Top Insulin Biologics and Biosimilars Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Insulin Biologics and Biosimilars Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Insulin Biologics and Biosimilars, Headquarters and Area Served

Table 20. Global Key Players of Insulin Biologics and Biosimilars, Product and Application

Table 21. Global Key Players of Insulin Biologics and Biosimilars, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Insulin Biologics and Biosimilars Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2020-2025)

Table 25. Global Insulin Biologics and Biosimilars Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2026-2031)

Table 27. Global Insulin Biologics and Biosimilars Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2020-2025)

Table 29. Global Insulin Biologics and Biosimilars Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2026-2031)

Table 31. North America Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Insulin Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Insulin Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Insulin Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Insulin Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Insulin Biologics and Biosimilars Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Insulin Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Insulin Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2026-2031) & (US$ Million)

Table 46. Novo Nordisk Company Details

Table 47. Novo Nordisk Business Overview

Table 48. Novo Nordisk Insulin Biologics and Biosimilars Product

Table 49. Novo Nordisk Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 50. Novo Nordisk Recent Development

Table 51. Eli Lilly Company Details

Table 52. Eli Lilly Business Overview

Table 53. Eli Lilly Insulin Biologics and Biosimilars Product

Table 54. Eli Lilly Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 55. Eli Lilly Recent Development

Table 56. Sanofi Company Details

Table 57. Sanofi Business Overview

Table 58. Sanofi Insulin Biologics and Biosimilars Product

Table 59. Sanofi Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 60. Sanofi Recent Development

Table 61. Gan&Lee Company Details

Table 62. Gan&Lee Business Overview

Table 63. Gan&Lee Insulin Biologics and Biosimilars Product

Table 64. Gan&Lee Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 65. Gan&Lee Recent Development

Table 66. Tonghua Dongbao Company Details

Table 67. Tonghua Dongbao Business Overview

Table 68. Tonghua Dongbao Insulin Biologics and Biosimilars Product

Table 69. Tonghua Dongbao Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 70. Tonghua Dongbao Recent Development

Table 71. United Laboratory Company Details

Table 72. United Laboratory Business Overview

Table 73. United Laboratory Insulin Biologics and Biosimilars Product

Table 74. United Laboratory Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 75. United Laboratory Recent Development

Table 76. Geropharm Company Details

Table 77. Geropharm Business Overview

Table 78. Geropharm Insulin Biologics and Biosimilars Product

Table 79. Geropharm Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 80. Geropharm Recent Development

Table 81. Biocon Company Details

Table 82. Biocon Business Overview

Table 83. Biocon Insulin Biologics and Biosimilars Product

Table 84. Biocon Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 85. Biocon Recent Development

Table 86. Wockhardt Company Details

Table 87. Wockhardt Business Overview

Table 88. Wockhardt Insulin Biologics and Biosimilars Product

Table 89. Wockhardt Revenue in Insulin Biologics and Biosimilars Business (2020-2025) & (US$ Million)

Table 90. Wockhardt Recent Development

Table 91. Research Programs/Design for This Report

Table 92. Key Data Information from Secondary Sources

Table 93. Key Data Information from Primary Sources

Table 94. Authors List of This Report

List of Figures

Figure 1. Insulin Biologics and Biosimilars Picture

Figure 2. Global Insulin Biologics and Biosimilars Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Insulin Biologics and Biosimilars Market Share by Type: 2024 VS 2031

Figure 4. Insulin Biologics Features

Figure 5. Insulin Biosimilars Features

Figure 6. Global Insulin Biologics and Biosimilars Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Insulin Biologics and Biosimilars Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Retail Pharmacy Case Studies

Figure 10. Other Case Studies

Figure 11. Insulin Biologics and Biosimilars Report Years Considered

Figure 12. Global Insulin Biologics and Biosimilars Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Insulin Biologics and Biosimilars Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Insulin Biologics and Biosimilars Market Share by Region: 2024 VS 2031

Figure 15. Global Insulin Biologics and Biosimilars Market Share by Players in 2024

Figure 16. Global Top Insulin Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin Biologics and Biosimilars as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Insulin Biologics and Biosimilars Revenue in 2024

Figure 18. North America Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Insulin Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 20. United States Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Insulin Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 24. Germany Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Insulin Biologics and Biosimilars Market Share by Region (2020-2031)

Figure 32. China Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Insulin Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 40. Mexico Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Insulin Biologics and Biosimilars Market Share by Country (2020-2031)

Figure 44. Turkey Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Insulin Biologics and Biosimilars Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Novo Nordisk Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 48. Eli Lilly Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 49. Sanofi Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 50. Gan&Lee Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 51. Tonghua Dongbao Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 52. United Laboratory Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 53. Geropharm Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 54. Biocon Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 55. Wockhardt Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2020-2025)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Biosimilar Insulin Market

Global Innovations in Biologics and Biosimilars Market Research Report 2024

Global Biologics and Biosimilars Market Research Report 2025

Innovative Biologics and Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Insulin Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biotech Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Glucagon Injection Market Research Report 2025

Glucagon Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Glucagon Market Research Report 2025

Innovative Biologics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Insulin Storage Devices Market Research Report 2024

Global Recombinant Human Insulin Market Insights Forecast to 2030

Global Generic vs Innovator Drugs Market Research Report 2024

Global Insulin Drugs for Diabetes Market Research Report 2024

Global Insulin Coolers Market Research Report 2024

Global Hormonal Therapy for Type 2 Diabetes Market Research Report 2024

Global Human Insulin Market Research Report 2024

Global Pancreatic Beta Cell Protection Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions